Survival outcomes of allogeneic hematopoietic cell transplants with EBV-positive or EBV-negative post-transplant lymphoproliferative disorder, A CIBMTR study.
Seema G NaikMarcie RichesParameswaran HariSoyoung KimMin ChenCarlos BachierPaul ShaughnessyJoshua HillPer LjungmanMinoo BattiwallaSaurabh ChhabraAndrew DalyJan StorekCelalettin UstunMiguel Angel DiazJan CernyAmer BeitinjanehJean YaredValerie BrownKristin PageParastoo B DahiSiddhartha GangulySachiko SeoNelson ChaoCesar O FreytesAyman SaadBipin N SavaniKwang Woo AhnMichael BoeckhHelen E HeslopHillard M LazarusJeffery J AulettaRammurti T KamblePublished in: Transplant infectious disease : an official journal of the Transplantation Society (2019)
There is no difference in survival outcomes for patients with EBVpos or EBVneg PTLD occurring following alloHCT and 1-year survival is poor. Features of conditioning and use of serotherapy remain important.